1. Pharmacist Perspectives on Novel Agents in Multiple Myeloma

2. Learning Objectives

3. MM Therapy Progression

4. Recently Approved Agents

5. Patient Case 1

6. Ixazomib

7. Ixazomib Drug Interactions

8. TOURMALINE-MM1 Ixazomib + Len/Dex vs Placebo + Len/Dex

9. TOURMALINE-MM1 Toxicity

10. Ixazomib Practical Points

11. Patient Case 2

12. Monoclonal Antibodies

13. ELOQUENT-2 Elotuzumab + Len/Dex vs Len/Dex

14. ELOQUENT-2 Toxicity

15. Elotuzumab Practical Points

16. Patient Case 3

17. Daratumumab

18. Daratumumab Monotherapy Phase 2 Study, ≥ 3 Lines of Prior Therapy

19. Daratumumab Additional Points

20. Daratumumab Combination Treatment CASTOR and POLLUX

21. CASTOR and POLLUX Efficacy

22. CASTOR and POLLUX Toxicity

23. CASTOR and POLLUX IRRs

24. Future Directions

25. Select Therapies in Development

26. Abbreviations

27. Abbreviations (cont)

28. Abbreviations (cont)

29. Abbreviations (cont)